Whitney Duff is the Clinical Research Lead at ZYUS Life Sciences, a Canadian pharmaceutical company specializing in cannabinoid-based therapies. With a PhD in Clinical Research from the University of Saskatchewan, she leads clinical trial design, regulatory alignment, and implementation—most notably as the lead investigator of the first-in-human HOPE study for Trichomylin®, a novel cannabinoid formulation for managing chronic osteoarthritis pain.

In her role, Whitney bridges scientific insight with regulatory precision, ensuring that study protocols meet compliance standards while prioritizing patient safety. Her work supports ZYUS’s mission to advance evidence-based cannabinoid therapies through rigorous clinical development and regulatory excellence.